Cart
sales@molnova.com
BRD6989
CAS No. 642008-81-9
BRD6989( BRD-6989 | BRD 6989 )
Catalog No. M15440 CAS No. 642008-81-9
A novel potent, selective CDK8 inhibitor with IC50 of 0.5 uM against recombinant Cyclin C/CDK8 complex; displays no activity against several CDKs involved in cell cycle including CDK19 (IC50>30 uM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 60 | Get Quote |
|
| 10MG | 88 | Get Quote |
|
| 25MG | 186 | Get Quote |
|
| 50MG | 332 | Get Quote |
|
| 100MG | 494 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBRD6989
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel potent, selective CDK8 inhibitor with IC50 of 0.5 uM against recombinant Cyclin C/CDK8 complex; displays no activity against several CDKs involved in cell cycle including CDK19 (IC50>30 uM).
-
DescriptionA novel potent, selective CDK8 inhibitor with IC50 of 0.5 uM against recombinant Cyclin C/CDK8 complex; displays no activity against several CDKs involved in cell cycle including CDK19 (IC50>30 uM); inhibits IFNγ-induced phosphorylation of STAT1 at Ser 727 site in BMDCs, selectively upregulates IL-10 with EC50 of 1 uM.
-
In Vitro——
-
In Vivo——
-
SynonymsBRD-6989 | BRD 6989
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number642008-81-9
-
Formula Weight264.332
-
Molecular FormulaC16H16N4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (94.58 mM)
-
SMILESCC1CCC2=C(C1)C(=C(C(=N2)N)C#N)C3=CN=CC=C3
-
Chemical Name2-amino-6-methyl-4-(pyridin-3-yl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Johannessen L, et al. Nat Chem Biol. 2017 Oct;13(10):1102-1108.
molnova catalog
related products
-
CDK4/6-IN-6
CDK4/6-IN-6 is a potent CDK4/CDK6 inhibitor with Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively.
-
iCDK9
iCDK9 (i-CDK9) is a potent, highly selective CDK9 inhibitor (IC50<0.4 nM, CDK9-CycT1 kinase), exhibits >600-fold selectivity toward CDK1-CycB, CDK2-CycA, CDK4-CycD1, CDK7-CycH-MAT1 and CDK8-CycC.
-
THZ2
THZ2, an analogue of THZ1 with improved pharmacokinetic features, is a potent, selective CDK7 inhibitor with IC50 of 13.9 nM, displays a 5-fold improved half-life in vivo compared with THZ1.
